Skip to content

Categories: cancer

Miika Martikainen and Magnus Essand, researchers at Uppsala University. Photo: Private/Mikael Wallerstedt

Route of entry for Semliki Forest virus into the brain revealed

A recent study shows that the Semliki Forest virus enters the central nervous system by first entering the cerebrospinal fluid and then binding to a specific cell type before penetrating deeper into the brain. This finding could potentially be used to develop the Semliki Forest virus as an agent for treating brain cancer. The study has been published in the journal Nature Communications.

A graphical summary illustrates the strategy used to identify CYP2D6 as a target for collateral lethality, which is driven by the widespread occurrence of loss of heterozygosity in cancer genomes.

Genetic variation enhances cancer drug sensitivity

By exploiting the genetic variation in cancer cells, an already approved cancer drug demonstrated enhanced effects against cancer cells in specific patient groups. This is shown in a recent study from Uppsala University, published in the journal eBiomedicine. The findings suggest a potential for more individually tailored and more effective cancer therapies.

New antibody could be promising cancer treatment

New antibody could be promising cancer treatment

Researchers at Uppsala University and KTH Royal Institute of Technology have developed a new form of precision medicine, an antibody, with the potential to treat several types of cancer. Researchers have managed to combine three different functions in the antibody, which together strongly amplify the effect of T cells on the cancer tumour. The study has been published in Nature Communications.

Anna Bill-Axelson, Professor of Urology, Department of Surgical Sciences, Uppsala University. Photographer: Mikael Wallerstedt

Early prostate cancer surgery extended life

The survival rate of men with prostate cancer who had their entire prostate gland removed immediately after the tumour was detected increased by 17 percentage points compared with those who did not have treatment until the tumour began to cause symptoms. On average, they also lived more than two years longer. These are the final results of a 30-year Scandinavian study led from Uppsala University.

Bengt Glimelius, Senior Professor of Oncology at Uppsala University and Senior Consultant at Uppsala University Hospital.

Promising treatment for rectal cancer confirmed in major study

A new treatment for locally advanced rectal cancer shows favourable results in that surgery can sometimes be avoided completely. It also reduces the risk of recurrence. The method has been confirmed as effective in a comprehensive study conducted at Uppsala University and published in eClinicalMedicine.

Luis Nunes, researcher at the Department of Immunology, Genetics and Pathology at Uppsala University and one of the first authors of the study. Photo: Mikael Wallerstedt

Genetic signatures provide prognostic information in colorectal cancer

Using a unique collection of genetic and clinical data for colorectal cancer, researchers at Uppsala University have revealed genetic new alterations and developed of a new molecular classifier of tumour variants. The finding could lead to improved possibilities for individualised therapies. This is shown in study recently published in the journal Nature.

Ingrid Glimelius, Professor and Senior Physician in Oncology at Uppsala University Hospital and Uppsala University. Photo: Mikael Wallerstedt.

Lymphoma patients at high risk of infections after diagnosis

Every year, around 100 people are affected by mantle cell lymphoma. A study at Uppsala University shows that these patients are more vulnerable to other diseases and that the risk of infection for this type of patient should therefore be carefully evaluated. The results of the study have been published in the journal Hemasphere.

Camilla Sköld, Specialist Physician in Gynaecological Cancer at the Oncology Clinic, Uppsala University Hospital, researcher at Uppsala University. Photo: Anthoula Koliadi

Lower survival rates for women than men with germ cell tumours

Women with a type of ovarian cancer known as germ cell tumours have a worse prognosis than men with similar tumours, i.e. testicular cancer. After five years with the disease, 98 percent of men were alive while the survival rate for women was only 85 percent. This has been revealed by a new study from Uppsala University and Uppsala University Hospital published in the Journal of Internal Medicine.

Some increase in cancer after 1986 Chernobyl disaster

The nuclear accident in Chernobyl in 1986 led to the spread of radioactivity across Sweden and Europe. In a long-term study now published in Environmental Epidemiology, researchers have used new, more specific calculation methods to show the connection between radiation dose and certain types of cancer.

Men with metastatic prostate cancer live longer thanks to new drugs

Survival rates for men with metastatic prostate cancer have increased by an average of six months, something which coincides with the gradual introduction of ‘dual treatment’ since 2016. This is according to a register study of all Swedish men diagnosed between 2008 and 2020. The results are published in the medical journal JAMA Network open.

New method to identify mutations in childhood brain tumors

Researchers at Uppsala university have developed a new method to find mutations in brain tumors in children. They could also show that the mutations identified by them changes how cancer cells respond to a cancer drug. These findings could lead to better diagnostics and more individualized treatment of children with brain tumors. The study is published in the journal PNAS.

AAV-LIGHT therapy changes the phenotype of the tumor vessels and enable T cell infiltration into the tumor. Created with Biorender.

New therapy helps immune system eradicate brain tumours

Researchers from Uppsala University have developed a method that helps immune cells exit from blood vessels into the tumour and kill cancer cells. The aim is to improve treatment of aggressive brain tumours. The study has been published in the journal Cancer Cell.

Increased risk of testicular cancer in people with neurodevelopmental disorders

A new study by researchers at Uppsala University and Uppsala University Hospital shows that men who have a neurodevelopmental disorder, such as autism and ADHD, also have a slightly increased risk of testicular cancer, or seminoma. This is the first study to show such a link, with the results to be published in the British Journal of Cancer.

Combination of immune cells could provide clearer prognoses for cancer

Thanks to a new prognostic method for detecting cancers including cancer of the large intestine, doctors could provide clearer disease prognoses and predict which patients will respond best to immunotherapy. The method consists of a combination of two types of immune cells that characterise certain forms of cancer. This has been shown in a new study published in the journal eBioMedicine.

Immunofluorescence staining of a human lymph node with early stage lipomatosis (fat) in the medullary area of the lymph node. Credit: Tove Bekkhus

How fat takes over the lymph nodes as we age

A new study from researchers at Uppsala University presents novel findings on why human lymph nodes lose their function with age and the consequences for the effectiveness of our immune system. The article has been published in The Journal of Pathology.

A stem cell protein facilitates relapse of pediatric brain tumours

The malignant brain tumour type medulloblastoma can become resistant to therapy which can cause relapse. Researchers at Uppsala University have discovered a certain protein that makes tumour cells resting and insensitive to radiation treatment. The research group hopes that the results could eventually lead to better treatments for children that have the highest risk to develop relapses.

Subgroups of glioblastoma associated with disease prognosis

Researchers at Uppsala University have detected different subgroups of the brain tumour form glioblastoma, where the cancer cells’ properties depend on which cell type they originate from. The used analysis method could also separate glioblastoma patients with significant differences in survival. The findings open up for identifying specific therapeutic targets for the new subgroups of glioblastom

Armed CAR-T cells to better fight cancer

Immunotherapy is increasingly becoming a successful way to treat cancer. Researchers at Uppsala University have now developed armed CAR-T cells that reinforce the immune defence against cancer and that could increase the possibilities to successfully treat solid tumours. The study has been published in the journal Nature BioMedical Engineering.

Uppsala University - quality, knowledge, and creativity since 1477

Founded in 1477, Uppsala University is the oldest university in Sweden. With more than 50,000 students and 7,500 employees in Uppsala and Visby, we are a broad university with research in social sciences, humanities, technology, natural sciences, medicine and pharmacology. Our mission is to conduct education and research of the highest quality and relevance to society on a long-term basis. Uppsala University is regularly ranked among the world’s top universities.

Uppsala University

Dag Hammarskjölds väg 7
BOX 256, 751 05 Uppsala
Sweden

Visit our other newsrooms